Samsung Biologics Makes $1.8 Billion All-Cash Offer for Switzerland's PolyPeptide Group
Samsung Biologics has launched a 1.46 billion Swiss franc ($1.8 billion) all-cash tender offer for Switzerland's PolyPeptide Group, a peptide-based drug ingredient specialist, in what the South Korean firm describes as the largest biopharmaceutical M&A deal in its country's history.